Herantis Pharma Plc

As of June 30, 2026, Herantis Pharma Plc carries a market capitalization of 48.77M, placing it among publicly traded companies globally. Its enterprise value stands at 45.28M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Herantis Pharma Plc's next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2026, Herantis Pharma Plc has 26.50M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Herantis Pharma Plc maintains a current ratio of 2.89, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Herantis Pharma Plc's stock has declined approximately 44.27% over the past 52 weeks. The 50-day moving average sits at 1.47, while the 200-day moving average is 1.79.

As of June 30, 2026, Herantis Pharma Plc holds 3.51M in cash and equivalents against 20,000.00 in total debt, resulting in a net debt position of -718,000.00. Total book value stands at -796,000.00, with working capital of 2.64M providing operational flexibility.

Herantis Pharma Plc's most recent stock split took place on May 4, 2022 with a 447:470 split ratio.